Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Michael Stocum to Step Down as Inivata CEO
Search for new CEO is underway
Research Triangle Park, NC and Cambridge, UK, May 8, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care announces that Michael Stocum has stepped down as CEO to pursue other interests.
Michael Stocum said, "It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years. The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills."
Jeff Buchalter, Chairman, said, "I would like to thank Mike for his significant contribution to Inivata and wish him well in his future endeavours. Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. I look forward to the next phase of the Company's development with considerable confidence."
The Company has initiated a search for a new CEO.
About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
[email protected] +44 (0)20 3709 5700
Karen Chandler-Smith
[email protected] +44 (0)7900 430235
